| Downregulation of PA28alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. | Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Gu Y, Barwick BG, Shanmugam M, Hofmeister CC, Kaufman J, Nooka A, Gupta V, Dhodapkar M, Boise LH, Lonial S., Free PMC Article | 05/8/2021 |
| Conformational maps of human 20S proteasomes reveal PA28- and immuno-dependent inter-ring crosstalks. | Conformational maps of human 20S proteasomes reveal PA28- and immuno-dependent inter-ring crosstalks.
Lesne J, Locard-Paulet M, Parra J, Zivković D, Menneteau T, Bousquet MP, Burlet-Schiltz O, Marcoux J., Free PMC Article | 12/19/2020 |
| Such a modulation of proteasome activity is explained, at least in part, by the circadian expression of both Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the proteasome activator PA28ab | Circadian modulation of proteasome activity and accumulation of oxidized protein in human embryonic kidney HEK 293 cells and primary dermal fibroblasts.
Desvergne A, Ugarte N, Radjei S, Gareil M, Petropoulos I, Friguet B. | 12/23/2017 |
| Results show that PA28alpha was found to be overexpressed in oral squamous cell carcinoma cell lines and tumor tissues. High expression of PA28alpha was significantly associated with recurrence and poorer overall survival. | Overexpression of proteasomal activator PA28α serves as a prognostic factor in oral squamous cell carcinoma.
Feng X, Jiang Y, Xie L, Jiang L, Li J, Sun C, Xu H, Wang R, Zhou M, Zhou Y, Dan H, Wang Z, Ji N, Deng P, Liao G, Geng N, Wang Y, Zhang D, Lin Y, Ye L, Liang X, Li L, Luo G, Feng M, Fang J, Zeng X, Wang Z, Chen Q., Free PMC Article | 10/22/2016 |
| Constitutive expression of PA28 and ERAP1 in melanoma cells indicate that both interfere with MART-1(26-35) epitope generation even in the absence of IFN-gamma | The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.
Keller M, Ebstein F, Bürger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krüger E, Rothkötter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U. | 04/16/2016 |
| PA28 is a tumor marker and a potential target for therapeutic intervention in prostate cancer. | Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.
Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT, Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E, Alvarez-Vallina L., Free PMC Article | 11/30/2013 |
| Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNbeta in mouse pancreatic beta-cells. | Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNβ in mouse pancreatic β-cells.
Freudenburg W, Gautam M, Chakraborty P, James J, Richards J, Salvatori AS, Baldwin A, Schriewer J, Buller RM, Corbett JA, Skowyra D., Free PMC Article | 07/20/2013 |
| the first evidence of a novel ovarian cancer-specific marker | The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
Longuespée R, Boyon C, Castellier C, Jacquet A, Desmons A, Kerdraon O, Vinatier D, Fournier I, Day R, Salzet M. | 11/24/2012 |
| bortezomib-adapted HL-60 cells showed increased expression and proteasome association of the 11S proteasome activator | Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, Driessen C. | 01/21/2010 |
| the 11S proteasome activator complex, Reg alpha fragment, may have a role in ovarian cancer | Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.
Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. | 01/21/2010 |
| DJ-1 and PA28alpha may have roles in the onset of hepatocarcinogenesis | Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma.
Zhang D, Lim SG, Koay ES. | 01/21/2010 |
| PA28 selectively up-regulates the presentation of viral MHC class I epitopes and that down regulation PA28 in tumor cells results in impaired presentation of a human TRP2 tumor antigen. | The role of the proteasome activator PA28 in MHC class I antigen processing.
Sijts A, Sun Y, Janek K, Kral S, Paschen A, Schadendorf D, Kloetzel PM. | 01/21/2010 |
| The relationship between anti-PA28alpha and Ki antibodies suggests the importance of an antigen-driven system in the induction of an autoimmune response to PA28 complex. | Autoimmune response to proteasome activator 28alpha in patients with connective tissue diseases.
Matsushita M, Takasaki Y, Takeuchi K, Yamada H, Matsudaira R, Hashimoto H. | 01/21/2010 |
| Impaired expression of proteasome subunits is involved in the loss of HLA class I expression in human colon cancer cells. | Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells.
Miyagi T, Tatsumi T, Takehara T, Kanto T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N. | 01/21/2010 |